IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab

Affiliations

¹ The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
² Servicio de Reumatología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Paseo de la Castellana 261, Madrid, Spain.

Editorial

Yoshiya Tanaka et al. Ann Rheum Dis. 2014 Sep.

. 2014 Sep;73(9):1595-7.

doi: 10.1136/annrheumdis-2013-205002. Epub 2014 May 15.

¹ The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.
² Servicio de Reumatología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Paseo de la Castellana 261, Madrid, Spain.

No abstract available

Keywords: DMARDs (biologic); Rheumatoid Arthritis; Treatment.

Comment on

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.
Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K. Genovese MC, et al. Ann Rheum Dis. 2014 Sep;73(9):1607-15. doi: 10.1136/annrheumdis-2013-204760. Epub 2014 Mar 18. Ann Rheum Dis. 2014. PMID: 24641941 Free PMC article. Clinical Trial.